New two-year data confirm Roche’s Vabysmo improves vision with fewer treatments for people with neovascular age-related macular degeneration July 14, 2022July 14, 2022 by / Share This.....LinkedinTwitterFacebookGoogleEmailRelated News: New two-year data for Roche’s Vabysmo and Susvimo…New two-year data for Roche’s Vabysmo and Susvimo…New phase III data show Roche’s Vabysmo rapidly…Positive topline phase III results show Roche's…FDA approves Roche’s Vabysmo, the first bispecific…FDA approves Roche’s Vabysmo, the first bispecific…
